MET and hepatocellular carcinoma: We subsequently studied combination therapy with sorafenib and MK2 Inhibitor III in an AKT/MET HCC mouse model generated via hydrodynamic tail vein injection (HDTVi) of the Sleeping Beauty Transposon system to overexpress myr‐AKT and MET (c‐MET).